Ionis Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• ION363 · Cardiovascular
  ION363 is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III), a protein that impairs triglyceride clearance and increases cardiovascular risk.
• ION582 · Cardiovascular
  ION582 is an antisense oligonucleotide that reduces production of apolipoprotein B (ApoB) to lower LDL cholesterol levels.

Phase 2 pipeline

• GHR-LRX
• ION224
• ION904
• IONIS-AGT-LRx
• IONIS DGAT2Rx
• IONIS GHR-LRx · Endocrinology
  IONIS GHR-LRx is an antisense oligonucleotide that inhibits growth hormone receptor (GHR) expression to reduce growth hormone signaling.
• ISIS 104838
• ISIS 14803
• ISIS 416858
• ISIS 757456
• ISIS apoC-III Rx · Cardiovascular
  Antisense oligonucleotide that targets apolipoprotein C-III
• ISIS CRP Rx
• ISIS-FGFR4RX · Oncology
  Antisense oligonucleotide targeting fibroblast growth factor receptor 4
• ISIS-FXIRx Dose #2
• ISIS-FXIRx Dose #3
• ISIS-GCCRRx
• ISIS-GCGRRx
• ISIS-GCGRRx - Dose Level 1
• ISIS-GCGRRx - Dose Level 2
• ISIS-PTP1BRx · Metabolic/Endocrinology
  ISIS-PTP1BRx is an antisense oligonucleotide that inhibits protein tyrosine phosphatase 1B (PTP1B) to improve insulin signaling and glucose metabolism.

Phase 1 pipeline

• APOC-III-L-Rx
• BIIB094
• ION251
• ION356
• ION440
• ION464
• ION537
• ION547
• ION717
• IONIS ANGPTL3-LRx
• IONIS-DMPKRx
• IONIS-ENaCRx
• IONIS FXI-LRx
• IONIS MAPTRx
• IONIS-STAT3Rx
• IONIS TMPRSS6-Lrx
• ISIS 14803, peginterferon alfa, ribavirin
• ISIS 325568
• ISIS 353512
• ISIS 388626
• ISIS 443139 10 mg
• ISIS 443139 90 mg
• ISIS EIF4E Rx

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Ionis Pharmaceuticals, Inc. portfolio CI brief
• Ionis Pharmaceuticals, Inc. pipeline updates RSS